# Cellular DNA-Repair Longevity Stack (Conceptual)

Not a lab protocol. Ordered systems requirements for cells to maintain genome integrity longer.

## Pathways to cover

| Pathway | Lesions | Aging failure mode | Conceptual lever class |
|---------|---------|--------------------|------------------------|
| BER | Oxidized/deaminated bases | Mutation load, transcription stress | Glycosylase/AP-endonuclease capacity; antioxidant milieu |
| NER | Bulky adducts, UV | Transcription-coupled repair decline | TC-NER factor availability |
| MMR | Replication mismatches | Microsatellite/mutation accumulation | Preserve MMR in stem compartments |
| HR | DSBs (S/G2) | Shift to error-prone joiners | Favor HR in cycling stem cells |
| cNHEJ | DSBs (G1) | Indels, rearrangements | Avoid over-boosting mutagenic alt-EJ |
| DDR | Sensors | Persistent γH2AX / senescence | ATM/ATR–p53 balance; E2F repair transcriptome |

## Metabolic economy

```
Damage → PARP1 PARylation → NAD+ consumption
                ↘
            Sirtuins starve → chromatin/repair decline
CD38↑ with age → further NAD sink → inflammaging loop
```

**Design intent:** keep NAD available for both PARP *signaling* and sirtuin-supported genome maintenance; blunt CD38-driven sink; prevent chronic hyper-PARylation.

## Senescence coupling

Unrepaired damage → p16/p21 → E2F off → repair genes down → more transcriptional damage (mTORC1 on) → CCF → cGAS–STING → SASP.

**Break points:** restore E2F repair program without forced mitosis; activate p53 repair arm; clear/censor irreparable cells; reduce cytosolic DNA sensing inflammation.

## From insight → medicine

Any molecular intervention on this stack enters `design/medicine-pipeline.md` (target validation → IND → GMP → trials), with oncology surveillance mandatory.
